Revolution Medicines
RVMD
161.20
+1.77
+1.11%
Revolution Medicines
US · RVMD
#499 by market cap
Listed 2020
161.20
+1.77
+1.11%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q4).
- Total institutional ownership fell 1.3 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 99.79% -1.31pp
- Institutions
- 904 -3
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund55.85%
Hedge Fund29.25%
VC/PE Fund7.30%
Public Company2.50%
Private Company2.20%
Individual/Insider2.14%
Sovereign Wealth Fund1.14%
Government Pension Fund1.09%
Family Office/Trust0.26%
Top holders as of 2026-09-30
FMR
7.00% · 15.13M sh
BlackRock
6.41% · 13.86M sh
Farallon Capital Management, L.L.C.
6.20% · 13.42M sh
Baker Bros. Advisors LP
4.92% · 10.64M sh
Darwin Global Management Limited
4.91% · 10.63M sh
Vanguard Capital Management, LLC
4.84% · 10.47M sh
Vanguard Portfolio Management, LLC
3.77% · 8.16M sh
Nextech Invest Ltd.
3.51% · 7.60M sh
Janus Henderson Group plc
3.50% · 7.57M sh
UBS Asset Management
2.90% · 6.28M sh
Paradigm Biocapital Advisors LP
2.97% · 6.36M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 12 buys · 38 sells
| Name | Role | Stake |
|---|---|---|
| Alexis Borisy | Lead Independent Director | 1.08% |
| Mark Goldsmith | Chief Executive Officer | 0.36% |
| Thilo Schroeder | Independent Director | 0.35% |
| Stephen Kelsey | Senior Advisor | 0.10% |
| Margaret Horn | Chief Operating Officer | 0.04% |
| Sandra Horning | Independent Director | 0.04% |
| Jack Anders | Chief Financial Officer | 0.03% |
| Xiaolin Wang | Executive Vice President of Integrated Portfolio Strategy & Management | 0.03% |
| Alan Bart Sandler | Chief Development Officer | 0.02% |
| Elizabeth Anderson | Independent Director | 0.02% |
| Wei Lin | Chief Medical Officer | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-10 | Alexis Borisy | Lead Independent Director | Other Disposition | -10,625 | -- |
| 2026-11-10 | Jack Anders | Chief Financial Officer | Derivative Exercise and Sale | -35,750 | $18.56–192.84 |
| 2026-11-08 | Anthony Mancini | Chief Global Commercialization Officer | Derivative Exercise and Sale | -811 | $33.62–200.00 |
| 2026-10-25 | Anthony Mancini | Chief Global Commercialization Officer | Derivative Exercise and Sale | -2,310 | $33.62–186.99 |
| 2026-09-28 | Alan Bart Sandler | Chief Development Officer | Automatic Disposition | -309 | $203.91–204.72 |
| 2026-09-28 | Alan Bart Sandler | Chief Development Officer | Derivative Exercise and Sale | -6,000 | $58.84–203.91 |
| 2026-09-24 | Anthony Mancini | Chief Global Commercialization Officer | Derivative Exercise and Sale | -3,121 | $33.62–200.54 |
| 2026-09-24 | Jeffrey Cislini | Senior Vice President | Automatic Disposition | -765 | $207.32 |
| 2026-09-23 | Anthony Mancini | Chief Global Commercialization Officer | Automatic Disposition | -587 | $200.00 |
| 2026-09-21 | Elizabeth Anderson | Independent Director | Automatic Disposition | -5,073 | $192.54–195.15 |
| 2026-09-21 | Elizabeth Anderson | Independent Director | Derivative Exercise and Sale | -5,070 | $1.12–192.54 |
| 2026-09-17 | Anthony Mancini | Chief Global Commercialization Officer | Automatic Disposition | -1,764 | $196.94 |
| 2026-09-15 | Mark Goldsmith | Chief Executive Officer | Open Market Disposition | -13,988 | $195.01–199.30 |
| 2026-09-15 | Margaret Horn | Chief Operating Officer | Automatic Disposition | -4,967 | $195.01–199.30 |
| 2026-09-15 | Stephen Kelsey | Senior Advisor | Open Market Disposition | -5,569 | $195.01–199.30 |
| 2026-09-15 | Alan Bart Sandler | Chief Development Officer | Automatic Disposition | -341 | $194.96–199.30 |
| 2026-09-15 | Anthony Mancini | Chief Global Commercialization Officer | Open Market Disposition | -1,774 | $195.05–199.30 |
| 2026-09-15 | Jack Anders | Chief Financial Officer | Open Market Disposition | -4,053 | $195.00–199.30 |
| 2026-09-15 | Jeffrey Cislini | Senior Vice President | Open Market Disposition | -3,366 | $195.01–199.30 |
| 2026-09-14 | Mark Goldsmith | Chief Executive Officer | Intent to Sell (Form 144) | -13,603 | $203.77 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.
Revolution Medicines discussion 0 comments